Evidence map›Paper›PMID 28470051›Full record

ArticleACS central science2017

Roger R Nani, Alexander P Gorka, Tadanobu Nagaya, Tsuyoshi Yamamoto, Joseph Ivanic, Hisataka Kobayashi, Martin J Schnermann

Abstract read
In one paragraph

Article in ACS central science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed.

  1. Control of Gemcitabine Activity With Blue and Red Light.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. A hydrophobic photouncaging reaction to profile the lipid droplet interactome in tissues.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  9. Article
  10. Article
  11. Review
  12. Light in a Heartbeat: Bond Scission by a Single Photon above 800 nm.Journal of the American Chemical Society · 2024
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Visible and NIR light photoactivatableRSC medicinal chemistry · 2023
    Article
  18. Article
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Roger R NaniChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.
Alexander P GorkaChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.
Tadanobu NagayaMolecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20850, United States.
Tsuyoshi YamamotoChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.
Joseph IvanicAdvanced Biomedical Computing Center, DSITP, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland 21702, United States.
Hisataka KobayashiMolecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20850, United States.
Martin J SchnermannChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.

Funding

Cancer-cell specific therapy: photo-immunotherapyZIABC011513 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KOBAYASHI, HISATAKA · 2013 to 2025
$15.5M
Near-IR Photorelease Chemistry: Discovery and ApplicationsZIABC011564 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SCHNERMANN, MARTIN · 2014 to 2025
$9.5M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS ZIA BC011564NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

Near-IR photocaging groups based on the heptamethine cyanine scaffold present the opportunity to visualize and then treat diseased tissue with potent bioactive molecules. Here we describe fundamental chemical studies that enable biological validation of this approach. Guided by rational design, including computational analysis, we characterize the impact of structural alterations on the cyanine uncaging reaction. A modest change to the ethylenediamine linker (

Identifiers

PMID28470051
PMCPMC5408340

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.